Seeing Through LEMS: From Early Detection to Advanced Management (CE Webcast)
Activity Description and Purpose
This educational activity focuses on Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder affecting the neuromuscular junction, leading to muscle weakness, fatigue, and autonomic dysfunction. It is often associated with ophthalmic symptoms such as diplopia and ptosis. This presents an imperative for primary eye care providers to include LEMS in their differential to potentially shape patients' health care outcomes decisively. The activity aims to enhance the understanding of LEMS among optometrists, covering its pathophysiology, diagnostic criteria, and treatment options. Participants will learn to identify clinical features, implement appropriate diagnostic measures, and evaluate clinical trial data on treatments through interactive case studies and expert discussions. By the end of the activity, optometrists will be better equipped to recognize LEMS, facilitate early diagnosis, and collaborate in the management of this complex condition.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Implement referrals according to the clinical features of Lambert-Eaton myasthenic syndrome
- Identify the appropriate diagnostic measures for Lambert-Eaton myasthenic syndrome
- Evaluate clinical trial data on treatment for Lambert-Eaton myasthenic syndrome
Faculty
Andrew G. Lee, MD
| |
John J. Chen, MD, PhD Professor of Ophthalmology and Neurology Neuro-ophthalmology Fellowship Director Mayo Clinic Rochester, Minnesota
| |
T. Aaron Judd, OD Board-Certified Optometrist Quigley Eye Specialists Fort Myers, Florida
|
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Faculty
John J. Chen, MD, PhD, is a consultant for Amgen Inc and UCB SA.
T. Aaron Judd, OD, has no relevant commercial relationships to disclose.
Andrew G. Lee, MD, is a consultant for AstraZeneca and Bristol-Myers Squibb Company; is an advisory board member of Stoke Therapeutics and Viridian Therapeutics, Inc; and is on the speakers bureau for Alexion Pharmaceuticals, Inc and Amgen Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Robert M. Geist IV, MD, has no relevant commercial relationships to disclose.
Accreditation Statement
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 92188-NO (Asynchronous)
COPE Course Category: Neuro-optometry
Administrator:
This activity, COPE Activity Number 128802, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Catalyst Pharmaceuticals, Inc, for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Catalyst Pharmaceuticals, Inc.
This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 325
Available Credit
- 1.00 COPE